Pharmacokinetics of Once-Daily Amikacin in Korean Adult Patients

Hye Kyung Kim¹, Eun Hee Ji², Bo Sook Ahn¹, Wan Gyoong Shin², and Jung Mi Oh²,⋆

¹Department of Pharmacy, Gangnam Severance Hospital, 712 Eonju-no, Gangnam-gu, Seoul 135-720, Korea
²College of Pharmacy, Seoul National University, Bldg 17-106, 28 Yeongeon-dong, Jongno-gu, Seoul 110-799, Korea

(Received May 3, 2011 · Revised June 21, 2011 · Accepted July 4, 2011)

Aminoglycosides are the major components for the empirical treatment of infections caused by gram-negative organisms.¹,² Two major toxicities associated with the use of aminoglycosides are nephrotoxicity and otoxicity.³-⁶ Nephrotoxicity is related to the duration of exposure rather than the high serum levels. On the other hand, ototoxicity is related to the elevated trough concentration, which is sometimes irreversible.³,⁴,⁶,⁷ A suggested approach to reducing these toxicities is to decrease the dosing frequency. As a result, a new dosage strategies for administering aminoglycosides, namely extended-dosing intervals and once-daily dosing regimen, are increasingly being practiced.⁷,⁸ Unlike that of β-lactams, the rate and extent of aminoglycoside’s capability against gram-negative bacteria are more a function of the concentration of the antibiotic. As a result, a higher peak concentration (C_max) and a higher C_{peak}/MIC ratio produce a rapid and complete bactericidal effect and have been postulated to be the best predictors of therapeutic efficacy. Prolonged post-antibiotic effect, bactericidal activity, reduced potential for adaptive post-exposure, and decreased risk of nephrotoxicity and otoxicity are all associated with the once-daily regi-

Correspondence to: Jung Mi Oh
College of Pharmacy, Seoul National University
Bldg 17-106, 28 Yeongeon-dong, Jongno-gu, Seoul 110-799, Korea
Tel: +82-2-740-8551, Fax: +82-2-766-9560
E-mail: jmoh@snu.ac.kr
men.\textsuperscript{5,6,9} Many meta-analysis and clinical trials indicate that once-daily dosage of aminoglycosides is as effective as multiple-dosage regimen with similar or lower toxicity.\textsuperscript{10-12}

The pharmacokinetics of amikacin has large intra- and inter-patient variations due to several factors such as creatinine clearance (CLcr), gender, age, body weight, serum creatinine (Scr), and the presence of sepsis or cirrhosis.\textsuperscript{1,2,7,13-19} Interestingly, a recent study of the once-daily dose of amikacin with lower peak target concentrations in intensive care unit (ICU) patients reported good clinical responses (94\%) and bacteriologic responses (84\%) with no nephrotoxicity.\textsuperscript{3,4}

All previous studies recommend that amikacin should be administered with individualized dosing regimens that take into account the factors that influence amikacin’s pharmacokinetic parameters. However, these previous studies have several limitations in that they had insufficient population sizes, validation problems, and restricted-population patients’ groups, among many others.\textsuperscript{19} Although the use of once-daily aminoglycoside is becoming increasingly prevalent in Korea, the optimal once-daily dosing strategy remains unknown and no clear guideline for its monitoring is available. Dosing strategies in Korean patients have been based on pharmacokinetic data from Western populations. Thus, pharmacokinetic and pharmacodynamic studies of amikacin therapy need to be performed among various Korean subpopulations. This study aims to evaluate the pharmacokinetic parameters of a once-daily amikacin regimen in adult Korean patients and compare them according to renal function so as to help design the optimal regimen for individualized once-daily amikacin administration.

METHODS

Study Population

This retrospective study was undertaken for patients receiving amikacin once daily against gram-negative infection from March 2001 to March 2004 at a tertiary care university hospital in Seoul, Korea. Patients were included for analysis if they were over 18 years of age, have received two or more once-daily doses of amikacin, and have had steady state pre- and post-dose serum concentrations measured. Patients with endocarditis, burns and on hemodialysis were excluded from the evaluation.

Data Collection

Patient characteristics such as gender, age, weight, height, type of infection, underlying disease, baseline biochemical markers, number of treatment days, and dosing information were collected. Biochemical markers [e.g., Scr, blood urea nitrogen (BUN), albumin, serum hemoglobin (Hb), and serum amikacin concentration] were obtained on the day of each amikacin concentration measurement. Other information such as the patients’ total daily dose of amikacin, dosing interval, duration of infusion, and duration of therapy were collected.

The exact time of administration of amikacin was acquired from the nursing medication administration record, interviews of the charge nurse, and the data sheet maintained by the pharmacy department. The sampling time of amikacin was obtained from a medical technologist. Each patient’s CLcr, ideal body weight, and degree of obesity were calculated.

Drug Administration

A usual dose of 500 mg of amikacin in a 100mL normal saline solution was administered once daily in combination with one or more antibiotics. Clinical pharmacists adjusted the subsequent patients’ doses using the software program CAPCIL\textsuperscript{®} (Simkin Inc., FL, USA).

Drug Concentration Analysis

Two amikacin plasma samples at steady state were drawn from each of the patients who were receiving once-daily doses of amikacin. A post-dose sample was drawn 30-60 minutes after the completion of the 30-minute infusion of amikacin, whereas a pre-dose sample was drawn 60 minutes before the next dose. The serum concentrations of amikacin were determined by
means of fluorescence polarization immunoassay (Cobas Integra 800 analyzer, Roche, Germany). The lowest and highest limits of detection were 0.3 mg/L and 80 mg/L, respectively.

Criteria for Diagnosis of Infection
The diagnosis of infections was based on symptomatic, physical, histological, laboratory and radiological findings as well as bacteriological assessment through the isolation of a pathogen from an appropriate source. The definition of each infection was based on the standard definitions of the Center for Disease Control and Prevention (CDC). 20)

Pharmacokinetic Parameters of Amikacin
A pharmacokinetic analysis was performed for each patient using the CAPCIL® program. The pharmacokinetic parameters of amikacin including clearance (CL), half-life ($T_{1/2}$), and volume of distribution (Vd) were calculated using the multiple-point linear method. Individual patient data including serum concentrations, age, weight, height, gender, Scr, dosage history, and indication for therapy were entered into the CAPCIL® program. The measured levels that were less than 0.3 mg/L were revised to 0.15 mg/L. The therapeutic plasma concentration range of amikacin for its $C_{\text{peak}}$ and $C_{\text{trough}}$ were regarded to be between 1 mg/L and 40 mg/L. 3,15)

Comparison of Pharmacokinetic Parameters According to CLcr
To evaluate the difference between the pharmacokinetic parameters (CL, $T_{1/2}$, and Vd) of amikacin according to the renal function, the patients were classified into four subgroups based on their CLcr as follows: CLcr < 40 mL/min; 40 mL/min CLcr 60 mL/min; 60 mL/min < CLcr 90 mL/min; CLcr > 90 mL/min.

Statistical Analyses
ANOVA was used to evaluate the difference between the pharmacokinetic parameters $C_{\text{trough}}$ and $C_{\text{peak}}$ of amikacin in four subgroups divided by CLcr. Scheffe was used for post hoc analysis. The p-value of < 0.05 was considered statistically significant. Statistical analyses were performed using the SAS computer program (Windows 8.0 version).

RESULTS
Baseline characteristics of the patients
A total of 353 adult in-patients treated with once-daily doses of amikacin were included in the evaluation. Clinical pharmacists monitored these patients’ doses. Patient characteristics are shown in Table 1. The patients included in this study had significant variations in age, weight, height, and baseline biochemical markers as shown in Table 1. One hundred sixty-nine (45%) values are presented by mean ± SD (range).

<table>
<thead>
<tr>
<th>Table 1. Patient characteristics (n=353)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristics</strong></td>
</tr>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Male, n (%)</td>
</tr>
<tr>
<td>Female, n (%)</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Indication for therapy, n (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Underlying diseases, n (%)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Baseline biochemical markers</td>
</tr>
<tr>
<td>Serum BUN (mg/dL)</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
</tr>
<tr>
<td>Creatinine clearance (mL/min)</td>
</tr>
<tr>
<td>Serum albumin (g/dL)</td>
</tr>
<tr>
<td>Serum Hemoglobin (g/dL)</td>
</tr>
<tr>
<td>Administration of amikacin</td>
</tr>
<tr>
<td>Dose (mg/day)</td>
</tr>
<tr>
<td>Dose (mg/kg/day)</td>
</tr>
<tr>
<td>Duration (days)</td>
</tr>
</tbody>
</table>

SD, standard deviation; BUN, blood urea nitrogen
patients were 65 years of age or older. 194 (55%) patients had CLcr that was lower than 60 mL/min. 67 out of 353 total patients were admitted in the intensive care unit and CLcr was lower than 60 mL/min in 61% of them (n=41).

Most patients received amikacin once daily except for seventeen patients (4.8%) who received amikacin every other day. Seventy percent of the patients received 500 mg of amikacin once a day. Frequently administered concomitant antibiotics were penicillins (n = 47), third-generation cephalosporins (n = 258), macrolides (n = 42), and glycopeptides (n = 26).

**Pharmacokinetic Parameters of Amikacin**

The estimated values of CL, Vd, T_{1/2}, C_{peak}, and C_{trough} of amikacin are shown in Table 2. The number of patients with C_{trough} level between 1 and 5 mg/L or above 5 mg/L was 93 and 18, respectively. The ICU patients were noted to have higher C_{trough} levels than general ward patients, as 14.9% of ICU patients, compared to the 2.8% of general ward patients, had C_{trough} above 5 mg/L, as well as 44.8% of ICU patient, compared to the 22.0% of general ward patient, had C_{trough} between 1 and 5 mg/L. 40.3% of ICU patient and 75.2% of general ward patient had C_{trough} below 1 mg/L. The number of patients with C_{peak} levels between 40 and 50 was 35 and that with above 50 mg/L was 6.

**Comparison of Pharmacokinetic Parameters According to Creatinine Clearance**

CL, Vd, and T_{1/2} of amikacin stratified by CLcr were compared as shown in Figure 1. There were significant differences in the mean values of the CL, T_{1/2}, and Vd

![Figure 1](image-url)  
Fig. 1. Comparison of (A) clearance, (B) volume of distribution, and (C) half life of amikacin by creatinine clearance of patient.
among 4 groups stratified by CLcr (p<0.001 for all). Generally, CL and Vd of amikacin decreased whereas \( T_{1/2} \) increased when CLcr diminished. Post hoc analysis showed (1) clearance of amikacin with CLcr lower than 40 mL/min decreased significantly compared to CLcr higher than 60 mL/min, (2) volume of distribution with CLcr lower than 60 mL/min decreased significantly compared to CLcr higher than 90mL/min, and (3) half life with CLcr lower than 40 mL/min increased significantly compared to CLcr higher than 40mL/min. The estimated \( C_{\text{trough}} \) compared by CLcr had differences as shown in Figure 2. No difference was observed in the mean \( C_{\text{peak}} \) values of the patients with different states of renal function (p=0.4471).

**DISCUSSION**

Several studies have shown variability in the pharmacokinetic parameters of amikacin among patients with different underlying diseases.\(^1,2,3,15,16,18,19,21,22\) However, only limited data is available on the pharmacokinetic or pharmacodynamic variations of once-daily amikacin therapy in Korean adult patients with various underlying diseases and states. This study evaluated the pharmacokinetic parameters of once-daily amikacin doses in adult Korean patients. It is worth noting that most of the patients in the study received an 8.26±2.9 mg/kg dose for the once-daily dose of amikacin, which is lower than what has been recommended by literatures on once-daily amikacin administration.\(^1,7,12,15,21,23\) This may not have been a problem among our study patients, considering that many of them were old and had impaired renal functions. The most frequently administered (70%) dose of amikacin was 500 mg, given once a day. As a result, the mean \( C_{\text{peak}} \) and \( C_{\text{trough}} \) of amikacin were lower than what has been reported in other studies.\(^3,7,15,22,23\)

This study also showed that more ICU patients than general ward patients had \( C_{\text{trough}} \) levels above 1 mg/L, which might have been due to the impaired renal functions of the ICU patients. The amikacin dosage in patients with high \( C_{\text{trough}} \) levels were adjusted to keep their \( C_{\text{trough}} \) levels below 1 mg/L. Raveh *et al.* reported that renal damage is correlated with a high aminoglycoside trough level (> 1.1 mg/L), a low Hb level (< 10 g/dL), a hospital stay longer than 7 days prior to aminoglycoside treatment, and aminoglycoside treatment longer than 11 days.\(^4\) Moreover, several studies report that the nephrotoxicity associated with aminoglycoside treatment is related to the duration of the treatment.\(^5,6,9\) In the study conducted by Bacopoulou *et al.*, there were significant correlations between amikacin’s \( C_{\text{trough}} \) and its elimination rate constant, CL, or \( T_{1/2}. \)^\(^3\)

Clearance of amikacin has been reported to increase
Pharmacokinetics of Once-Daily Amikacin in Korean Adult Patients

Previous studies showed that CLcr was an important factor in the clearance of amikacin.\textsuperscript{1,3,15,19,22} Clearance of amikacin significantly differed according to CLcr. The mean clearance was lowest in patients with the most serious renal impairment (CLcr < 40 mL/min) and highest in patients with the least serious renal impairment (CLcr > 90 mL/min). Diabetes Mellitus (DM) has been shown to be a risk factor for nephrotoxicity.\textsuperscript{24,25} Therefore, patients with impaired renal functions or underlying diseases that influence their renal functions such as DM, or who have been admitted in ICU must have their amikacin dose monitored and adjusted according to their renal functions. In patients with severe renal dysfunction, a dose of every 48 hrs or longer is recommended. The mean T\textsubscript{1/2} of amikacin in the critically ill patients was larger than those found in other studies.\textsuperscript{2,3,21,22} Many studies have shown that the T\textsubscript{1/2} of amikacin increases in the presence of an impaired renal function and DM, and is strongly correlated with the elimination rate constant.\textsuperscript{2,3,21,22}

The mean V\textsubscript{d} of amikacin in this study was larger than what is reported for healthy volunteers but smaller than that of ICU patients.\textsuperscript{2,3,19}

One limitation of this study was that there were significant variations in the characteristics of the study population. Further studies with specific patient groups are needed. As suspected, a lower peak level was observed in the subjects since the dose that was administered was lower than what is traditionally recommended for once-daily doses. However, it is believed that this lower peak level was sufficient for the patient group, as a study by Bacopoulou \textit{et al.,} which included ICU patients, showed that a lower peak level for a once-daily amikacin dose has adequate efficacy with less nephrotoxicity.\textsuperscript{3} The optimal once-daily amikacin dosing regimen and the relationship between the C\textsubscript{peak} and C\textsubscript{trough} and the efficacy or toxicity of the regimen remain unknown, and there are no clear guidelines for monitoring the once-daily administration of aminoglycosides.\textsuperscript{5,26-30} Nevertheless, the results of this study indicate that the pharmacokinetic parameters of amikacin are influenced by CLcr. Therefore, the dose of amikacin should be individualized per patient, considering renal function to achieve its maximal therapeutic efficacy.

**CONCLUSION**

The mean C\textsubscript{trough} and C\textsubscript{peak} obtained from the low-dose, once-daily amikacin samples were 26.35±9.28 mg/L and 1.14±1.95 mg/L, respectively. The mean V\textsubscript{d}, CL, and T\textsubscript{1/2} were 0.35±0.16 L/kg, 55.40±23.72 mL/hr/kg, and 5.22±3.34 hrs, respectively. Clearance of amikacin with CLcr lower than 40 mL/min significantly decreased compared to that of CLcr higher than 60 mL/min. Volume of distribution with CLcr lower than 60 mL/min significantly decreased compared with that of CLcr higher than 90 mL/min. Half life with CLcr lower than 40 mL/min significantly increased compared with that of CLcr higher than 40 mL/min. C\textsubscript{trough}, of patients whose CLcr is lower than 40 mL/min were significantly higher than others, whereas C\textsubscript{peak} in various CLcr were not significantly different. This result indicates that the pharmacokinetic parameters of amikacin are dependent on CLcr, so the dose of amikacin should be individualized per patient for optimal effect.

**ACKNOWLEDGEMENT**

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0000354)

**REFERENCES**